His research is focused on the laboratory-based development and early phase clinical testing of cellular, viral and gene therapies for pediatric cancers and has been supported by numerous extramural grants including multiple R-, U- and P-level NIH grants. He has published over 150 peer-reviewed manuscripts and deliverd over 220 invited lectures. He is the principal investigator of a T32 training grant in pediatric cancer. He is the former chair of the FDA’s Cellular, Tissue and Gene Therapy Adivosry Committee. He serves as the editor-in-chief of the flagship cancer journal of the American Society of Cell and Gene Therapy, Molecular Therapy Oncology. He is co-founder and board member of Vironexis Biotherapeutics, Inc., a clinical stage cancer gene therapy company.